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Abstract 20 
Mesenchymal stromal cells (MSCs) hold great promise for regenerative medicine. Stable ex vivo gene 21 
transfer to MSCs could improve the outcome and scope of MSC therapy, but current vectors require 22 
multiple rounds of transduction, involve genotoxic viral promoters and/or the addition of cytotoxic 23 
cationic polymers in order to achieve efficient transduction. We describe a self-inactivating foamy virus 24 
vector (FVV), incorporating the simian macaque foamy virus envelope and using physiological 25 
promoters, which efficiently transduces murine MSCs (mMSCs) in a single-round. High and sustained 26 
expression of the transgene, whether GFP or the lysosomal enzyme, arylsulphatase A (ARSA), was 27 
achieved. Defining MSC characteristics (surface marker expression and differentiation potential), as well 28 
as long-term engraftment and distribution in the murine brain following intracerebroventricular delivery, 29 
are unaffected by FVV transduction. Similarly, greater than 95% of human MSCs (hMSCs) were stably 30 
transduced using the same vector, facilitating human application. This work describes the best stable gene 31 
transfer vector available for mMSCs and hMSCs. 32 
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Introduction 38 
Mesenchymal stromal cells (MSCs) are a heterogeneous population of adult cells of mesodermal origin 39 
that can be readily isolated from bone marrow or adipose tissue and efficiently expanded in vitro as 40 
plastic-adherent cells. They contain a proportion of cells capable of differentiating into osteocytes, 41 
adipocytes and chondrocytes under appropriate conditions1. MSCs have been extensively tested in a 42 
number of clinical conditions and proved enormous potential2. In vivo, tissue resident MSCs are thought 43 
to be recruited to sites of inflammation where they play a regulatory role in wound-healing, immune 44 
modulation, angiogenesis and tissue homeostasis3,4. Inflammation-directed trafficking may still be 45 
retained by exogenously administered MSCs, thus making the case for their use as cancer-targeting 46 
cells5,6 and site-directed immunosuppressive and pro-repair effector cells7, the latter being extensively 47 
exploited for a wide-range of diseases, such as rheumatoid arthritis, type-1 diabetes, and neurological 48 
diseases such as amyotrophic lateral sclerosis and stroke8,9. 49 
Long-term engraftment of MSCs in the central nervous system (CNS)10,11 facilitates their use as cellular 50 
vectors for neurodegenerative diseases, including Huntington’s disease12, Parkinson’s disease13 and 51 
lysosomal storage diseases14 which are caused by a lysosomal enzyme deficiency. Lysosomal enzymes 52 
are tagged with a mannose-6-phosphate to enable their retrieval from the secretory pathway by its binding 53 
to the mannose-6-phosphate receptor15. This retrieval is leaky, resulting in some secretion of lysosomal 54 
enzyme16. Secreted enzyme is then retrieved by mannose-6-phosphate receptor at the cell-surface. This 55 
secrete-and-recapture system can be exploited in gene and cell therapies since enzyme expression in one 56 
cell can correct many others. For example, metachromatic leukodystrophy (MLD), one of the most 57 
common lysosomal storage diseases, is caused by a deficiency of arylsulphatase A (ARSA) causing 58 
storage of sulphatide in oligodendrocytes, Schwann cells and neurons leading to progressive 59 
demyelination and, in its most common form, death by 5 years of age17. Over-expression of ARSA in 60 
hematopoietic stem cells can reduce sulphatide storage caused by ARSA deficiency in the CNS of mice18, 61 
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despite efficacy being dependent on the recruitment of microglia across the blood-brain-barrier. This 62 
demonstrates that relatively few cells expressing ARSA could be sufficient to prevent disease. Since 63 
MSCs can be safely delivered to humans, intravenously19 and directly to the brain20-22, a gene and MSC 64 
therapy could complement or exceed a hematopoietic stem cell-based approach. 65 
Any vector for gene transfer to MSCs should persist during cell division to allow ex vivo expansion. 66 
Vectors based on retroviruses, which integrate the vector DNA into the host genome readily achieve this. 67 
However, retroviral gene therapy trials have proven that these vectors carry a significant risk23,24 due to 68 
genotoxicity that is linked to the vectors’ integration sites, the presence of strong viral enhancers and/or 69 
transcriptional read-through25-28. Consequently, modern clinically relevant gene therapy vectors are 70 
deleted of promoter/enhancer activity from the viral LTRs (termed self-inactivating (SIN) vectors29) and 71 
employ non-viral physiological promoters to drive transgene expression30. Nonetheless, the commonly 72 
used integrating vectors (gamma-retroviral or lentiviral) have so far failed to transduce MSCs efficiently 73 
while retaining the aforementioned safety features31. Thus, a SIN vector with a physiological promoter 74 
that can efficiently transduce rodent and hMSCs would boost combined gene and MSC therapies. 75 
Foamy viruses are non-human, apathogenic viruses that form a distinct subgroup of the Retroviridae32,33. 76 
Self-inactivating foamy virus vectors (FVV) based on the prototype foamy virus (PFV) are well 77 
characterised34-38 and effective in large animal models of disease39,40. An historical disadvantage of FVVs 78 
is that they induced a marked cytopathic effect (CPE) at a high multiplicity of infection (MOI) in vitro 79 
due to the fusogenic nature of the PFV envelope (Env)32. The simian macaque foamy virus envelope 80 
(SFVmac Env) has recently been shown to be less fusogenic than that of PFV41, but has not been described 81 
in gene transfer. 82 
This paper describes optimisation of FVVs for high transduction efficiency and transgene expression in 83 
mMSCs and hMSCs. By employing the SFVmac Env, high transduction efficiencies (>95%) in MSCs are 84 
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achieved from a single-round of transduction by FVV containing the cellular phosphoglycerate kinase 85 
(PGK) promoter. Viral promoters or toxic chemicals are not involved and transgene expression is high 86 
and stable for at least 10 passages post-transduction. MSC differentiation potential and surface marker 87 
expression is preserved after FVV transduction at high MOI, as is the distribution and long-term 88 
engraftment of mMSCs delivered directly to the murine brain. Thus, we describe the best existing vector 89 
for stable MSC gene transfer. 90 
Results 91 
The PFV Env induces syncytia formation in target cells at high MOI. Since the less fusogenic SFVmac Env 92 
has not yet been tested in gene transfer, we compared the transduction efficiency in mMSCs of FVV with 93 
either the PFV or SFVmac Env at different MOIs and assessed the CPE microscopically. Aside from the 94 
alternative envelopes, both vectors were identical, each carrying the same PGK-GFP construct (all FVV 95 
constructs are shown in Fig. 1). Both envelopes produced good vector titres, typically ranging between 96 
108 and 109 HT1080 transducing units per ml after 100-fold concentration. Transduction efficiency was 97 
determined by flow cytometry as the percent of GFP expressing mMSCs following a single passage post-98 
transduction (Fig. 2a). At low MOIs of 1 and 5, the transduction efficiency for FVV with either the PFV 99 
or SFVmac Env was similar. At higher MOIs of 10 or more, the FVV with SFVmac Env resulted in 100 
significantly higher transduction efficiency than with PFV Env. This difference correlated with the MOI 101 
at which PFV Env induced extensive CPE, although syncytia formed at all MOIs tested using this 102 
envelope. In comparison, no CPE was observed even at the highest MOI of 50 for FVV with SFVmac Env. 103 
The highest transduction efficiency by FVV with PFV Env was achieved between MOIs of 30 and 50 104 
with 72% and 74% GFP-expressing cells, respectively, but was accompanied by a marked CPE. At the 105 
same MOIs, FVV with SFVmac Env achieved 92 and 95% transduction efficiency, respectively, with no 106 
CPE. Representative photomicrographs of mMSCs transduced at MOI 30 with each vector are shown in 107 
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Fig. 2 b-c, demonstrating the widespread syncytia induced only by PFV Env 20 hours after vector 108 
addition. All subsequent experiments employed FVV enveloped with SFVmac Env. 109 
The phosphoglycerate kinase (PGK) and elongation factor 1α short (EFS) promoters are constitutive 110 
cellular promoters that, in contrast to viral promoters, have performed well in sensitive genotoxicity 111 
assays that measure neighbouring gene activation30. The ability of these promoters to achieve high 112 
transduction efficiency and maintain expression of GFP in FVV transduced mMSCs through cell 113 
expansion, a pre-requisite for cell therapy manufacturing, was compared. Vectors FVV:PGK-GFP and 114 
FVV:EFS-GFP (Fig. 1), were used to transduce mMSCs at MOIs of 1, 30 and 50. Transduced mMSCs 115 
were analysed by flow cytometry to determine the percent of GFP expressing cells (Fig. 3a) and their 116 
median fluorescence intensity (MFI) (Fig. 3b) after each passage post-transduction up to the 10th passage 117 
(cells were passaged once confluence reached over 90% by reseeding one-tenth of the cells). This 118 
represents continuous culture over a period of 6 weeks. Representative photomicrographs of GFP 119 
fluorescence from MOI 30 transduced mMSCs is shown in Figs. 3 c,d. Since a MOI of 50 produced 120 
similar results to a MOI of 30 for both constructs at all passages, for clarity only data derived from a MOI 121 
of 30 are shown (Fig. 3). 122 
At a MOI of both 1 and 30, FVV:PGK-GFP transduction results in a higher percentage of mMSCs 123 
expressing GFP than FVV:EFS-GFP (Fig. 3a). Over 96% of mMSCs expressed GFP from 2 passages 124 
post-transduction with FVV:PGK-GFP and was sustained through subsequent passages. Comparatively, 125 
transduction with FVV:EFS-GFP at a MOI of 30 (or 50) only resulted in ~75% of mMSCs expressing 126 
GFP. At the low MOI of 1, most transduced cells contain a single vector copy (compared to multiple 127 
copies at high MOI), allowing for better analysis of expression persistence post-expansion. At this MOI, 128 
transduction with FVV:PGK-GFP enabled GFP expression in ~45% of mMSCs, stable over the 10 129 
passages. Conversely, the 40% of mMSCs expressing GFP at 1 passage post-transduction with FVV:EFS-130 
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GFP reduced to less than 15% by passage 4 post-transduction. Both EFS and PGK offer stable expression 131 
levels in the mMSCs that continue to express GFP, since the MFI does not change after repeated 132 
passaging (Fig. 3b). The PGK promoter drives approximately 5-fold higher GFP expression levels than 133 
EFS when mMSCs are transduced at a MOI of 30 from the second passage post-transduction, whereas the 134 
promoters performed similarly at one passage post-transduction. Together, Figs. 3a and b demonstrate 135 
the superiority of PGK as a promoter compared to EFS for FVV-mediated expression of GFP in mMSCs, 136 
providing higher expression levels, higher transduction rates and long-term stability. 137 
A codon optimised arylsulphatase A (ARSA) open reading frame replaced GFP in our FVVs to produce 138 
FVV:PGK-ARSA and FVV:EFS-ARSA (Fig. 1). For high transduction efficiency, mMSCs were 139 
transduced at a MOI of 30 with these FVVs and the transduced cells collected after 1 passage. One tenth 140 
of the cells were reseeded until the 5th passage post-transduction. The remaining cells were lysed to 141 
determine the intracellular ARSA activity by the ARSA assay42 (Fig. 4a). Low basal activity was detected 142 
by mMSCs transduced with FVV:PGK-GFP (control lysate). Both FVV:PGK-ARSA and FVV:EFS-143 
ARSA induced strong ARSA activity, the highest being at passage 2 post-transduction from both vectors. 144 
The PGK promoter resulted in a 2-fold higher enzyme activity at this passage. The ARSA activity 145 
remained stable over subsequent passages for FVV:PGK-ARSA transduced mMSCs, whereas the activity 146 
in FVV:EFS-ARSA transduced mMSCs reduced between each passage with a statistically significant 147 
reduction between passages 4 and 5 post-transduction. These data are in line with those generated for 148 
GFP expression. 149 
Since any MSC-based therapy for a lysosomal storage disease would depend on sufficient enzyme 150 
secretion and its correct processing with a mannose-6-phosphate to allow its recapture by endogenous 151 
cells, the ARSA activity in mMSC cell-culture medium and its ability to be taken up and used by MLD 152 
patients’ fibroblasts was determined. The control cell-culture medium from mMSCs transduced with 153 
FVV:PGK-GFP had a low ARSA activity (hydrolysing 3.3 nmol of substrate per hour per ml) (Fig. 4b), 154 
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whereas FVV:PGK-ARSA transduced mMSCs hydrolysed over 80 nmol of substrate per hour per ml, 155 
which was twofold higher than FVV:EFS-ARSA transduced mMSCs. Next, the FVV:PGK-ARSA 156 
transduced mMSCs cell-culture medium, or that from FVV:PGK-GFP (control medium), was incubated 157 
with normal (functional ARSA) or MLD patients’ (ARSA deficient) fibroblasts that had been preloaded 158 
with fluorescently labelled substrate (BODIPY-sulphatide). Media from both cultures were pre-diluted to 159 
the same extent, such that 0.5 units of ARSA (the amount needed to process 0.5 pmol of substrate per 160 
hour in the ARSA assay) was added to fibroblasts in the FVV:PGK-ARSA transduced mMSC medium. 161 
This dilution caused the contribution of endogenous ARSA to be negligible. Fibroblasts from normal 162 
donors stored only low amounts of BODIPY-sulphatide in the presence of control or FVV:PGK-ARSA 163 
transduced mMSC medium, as expected (Fig. 4c). Comparatively, fibroblasts from both MLD patients 164 
stored BODIPY-sulphatide in the presence of control medium. Storage was reduced when medium from 165 
FVV:PGK-ARSA transduced mMSCs was added, demonstrating that FVV:PGK-ARSA encoded ARSA 166 
is correctly processed by transduced mMSCs and can correct enzyme-deficient cells. 167 
The effects of FVV transduction on mMSC identity and function were examined by comparing 168 
untransduced mMSCs and mMSCs transduced at MOI 30 with FVV:PGK-GFP or FVV:PGK-ARSA. A 169 
panel of antibodies targeting surface markers known to be expressed or not in mMSCs was employed and 170 
staining assessed by flow cytometry. Transduced and untransduced mMSCs stained correctly for all 171 
markers with no discernible difference in staining intensity when quantified using the Flowjo Chi squared 172 
comparison (Fig. 5a,b). Similarly, transduced mMSCs were able to differentiate into osteocytes, 173 
chondrocytes and adipocytes to a similar extent as untransduced mMSCs when cultured under appropriate 174 
conditions (Fig. 5c-k). 175 
Given the prospect of using MSCs for therapy of diseases affecting the CNS, a sensitive qPCR targeting 176 
the Y-chromosome to allow detection of male mMSCs delivered directly to the brains of female mice43 177 
was established. To determine if FVV transduction affected the long-term engraftment capability of 178 
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mMSCs, untransduced or FVV:EFS-ARSA transduced male mMSCs were each injected into the right 179 
lateral ventricle of 6 female mice. Three months post-injection, treated mice were sacrificed and their 180 
brains crudely sectioned into 8 blocks (Fig. 6a). Genomic DNA was isolated from each block and the 181 
amount of male (mMSC-derived) DNA was determined by qPCR. The number of male genomes present 182 
per million total genomes (male and female) is shown for sections 1-8 in Fig. 6b. Data points are only 183 
shown for sections that exceeded the detection limit of approximately 10 male genomes per million. 184 
Section 6, which includes the injected ventricle (Fig. 6a), was the most likely section to contain 185 
detectable levels of mMSC DNA with 11 of the 12 injected mice having detectable levels. This section 186 
also tended to contain a higher proportion of male DNA than other sections. Section 3, containing the 187 
non-injected lateral ventricle, also featured high levels of male DNA in most treated mice. The 188 
cerebellum (section 8) was the least likely section to harbour mMSC DNA with only 2 mice having 189 
sufficient numbers for detection, both of which had been injected with FVV transduced mMSCs. Higher 190 
numbers of mice had detectable levels of male DNA in all other sections, showing that mMSCs migrate 191 
from the injected lateral ventricle throughout the brain. There was no discernible difference in distribution 192 
or level of engraftment between transduced and untransduced MSCs. 193 
To test whether FVV transduced mMSCs could maintain transgene expression in vivo, 6 adult mice were 194 
injected in their right lateral ventricle with FVV:PGK-GFP transduced mMSCs. Half the mice were 195 
sacrificed immediately post-injection and the other half after 45 days. Coronal cryosections of their brains 196 
were examined for direct GFP fluorescence (Fig. 6 c-f). Evidence of GFP expression was found for both 197 
time-points. The injected lateral ventricle contained many GFP-expressing cells immediately post-198 
injection and was enlarged, while the non-injected ventricle also contained some GFP-expressing cells. 199 
After 45-days, GFP-expressing cells were found predominantly, but not exclusively, associated with the 200 
choroid plexus; along the needle track route in the parenchyma; and in the glomerular layer of the 201 
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olfactory bulb. This shows that the PGK promoter remains active in FVV transduced mMSCs that have 202 
grafted long-term in the murine brain. 203 
To determine whether a FVV-based MSC therapy could be translated from pre-clinical work in mice to 204 
clinical use in humans, the GFP-encoding FVVs were tested on hMSCs obtained from 3 different donors. 205 
At an early passage number (2-4), the hMSCs were transduced with FVV:PGK-GFP or FVV:EFS-GFP at 206 
different MOIs. At a MOI of 50, we also tested transduction of these vectors employing the PFV Env. 207 
The results (Fig. 7a) show that, in contrast to results in mMSCs, the PFV Env achieved similar 208 
transduction efficiencies to SFVmac Env at high MOI. However, CPE was again induced by PFV Env, 209 
although to a lesser extent than in mMSCs at MOI 50 (not shown). At all MOIs and with either envelope, 210 
FVV:PGK-GFP and FVV:EFS-GFP perform similarly. For SFVmac Env containing FVVs, under 10% of 211 
hMSCs expressed GFP at MOI 1. Each increase in MOI tested resulted in a higher percent of GFP 212 
expressing hMSCs. At a MOI of 100, the highest tried, approximately 95% of hMSCs expressed GFP. 213 
Normal morphology and no CPE was observed by microscopy at this high MOI (Fig. 7 b-c). The average 214 
time between passages (one-fifth cells reseeded at each passage) for transduced and untransduced hMSCs 215 
was 4 days between each passage until the 7th post-transduction, where the time taken between passages 216 
doubled as cells putatively entered senescence. Transduced hMSCs retained normal osteogenic 217 
differentiation potential when tested at 6 passages post-transduction (not shown). Therefore, FVV 218 
transduction did not affect proliferation or function of hMSCs when assessed by these measures. 219 
Flow cytometry was performed for hMSCs transduced at MOIs of 1 and 100 with both FVV:PGK-GFP 220 
and FVV:EFS-GFP following each passage, until the 10th post-transduction, to monitor the percent of 221 
GFP expressing cells and their MFI (Fig. 7 d and e, respectively). During cell expansion, until growth 222 
slowed, neither the percent of hMSCs expressing GFP nor their MFI changed for hMSCs transduced with 223 
FVV:PGK-GFP or FVV:EFS-GFP at MOI 1 or 100. Both promoters exerted similar activity. At low 224 
MOI, there was variation in transduction efficiency of hMSCs from different donors, but this became 225 
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unapparent at high MOI. Following the putative entering of senescence, the percent of hMSCs expressing 226 
GFP reduced at a MOI of 1 from ~7% pre-senescence to less than 1% at the 9th passage post-transduction 227 
with FVV:EFS-GFP. A reduction was also observed for hMSCs transduced at low MOI with FVV:PGK-228 
GFP. At high MOI, the percent of GFP-expressing cells in FVV:PGK-GFP transduced hMSCs were 229 
unaffected by putative senescence, although the MFI became more variable between hMSCs from 230 
different donors. For just 1 of the 3 hMSCs transduced with FVV:EFS-GFP at high MOI, the percentage 231 
expressing GFP dropped from over 95% pre-senescence to 50.1% at the 8th passage post-transduction, 232 
resulting in the reduction in the average GFP expressing cells transduced with this vector. These data 233 
show that, at least pre-senescence, either of the tested FVVs are highly suited for high and stable 234 
transgene expression. 235 
 236 
Discussion 237 
All previous reports on FVVs have used the PFV envelope despite its toxicity to cells at high MOI. The 238 
SFVmac Env is less toxic since, in contrast to PFV Env, it only has significant fusion activity at low pH41, 239 
thus preventing fusion at the cell membrane. The PFV Env has extremely broad tropism, with only a 240 
single zebrafish cell line (Pac2) found to be resistant to PFV infection44. If the SFVmac Env permits broad 241 
tropism, its lack of toxicity would be advantageous. We have shown that for mMSCs, the SFVmac Env not 242 
only allows FVV use at high MOI without inducing syncytia, but unexpectedly enables higher 243 
transduction efficiencies to be achieved. Making this simple change may also benefit FVV transduction of 244 
other cell types. 245 
We compared the activity of two constitutive cellular promoters, EFS and PGK, in mMSCs and hMSCs 246 
over 10 passages. Unexpectedly, the promoter affected the observed transduction efficiency in mMSCs. 247 
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Since our measure of transduction efficiency depends on detectable GFP expression in each transduced 248 
cell, this result is likely caused by the absence of expression in some (FVV:EFS-GFP) transduced cells. 249 
This may be due to a combination of the unique integration site selection and/or the inherent 250 
heterogeneity within MSC populations. By monitoring expression through cell expansion (Fig. 3), it 251 
becomes apparent that the EFS promoter is subjected to putative silencing, as the percent of GFP-252 
expressing cells decreased during expansion. In contrast, the PGK promoter conferred stable expression 253 
which peaked at 2 passages post-transduction. This late peak may be explained by the FVV’s dependence 254 
on cell division for integration and transgene expression45. The silencing of EFS may also have played a 255 
role in reducing transduction rates using this promoter by counteracting the increase in GFP-expressing 256 
cells, since transduction of mMSCs with FVV:EFS-GFP at low MOI did not show a similar peak. 257 
Interestingly, neither the expression levels nor the observed transduction rates were influenced in hMSCs 258 
by promoter choice (Fig. 7), indicating different activities of these housekeeping genes between the 259 
species of MSCs tested. 260 
Using the lysosomal storage diseases as a proposed target, we showed that ARSA overexpression by 261 
FVVs in mMSCs results in strong enzyme activity with a significant amount being secreted. This secreted 262 
enzyme was appropriately processed since it could be used by ARSA deficient cells to clear stored 263 
substrate. Furthermore, we have shown that mMSC engraftment in the CNS is not affected by FVV 264 
transduction and in vivo transgene expression is maintained for at least 45 days. Our long-term 265 
engraftment levels and distribution was consistent with published results by an independent group using 266 
unmodified mMSCs43. Lack of a specific marker to identify MSCs in vivo prevents us from determining 267 
whether the GFP-expressing (MSC-derived) cells have maintained MSC identity or not. However, for the 268 
proposed use of long-term transgene expression, long-term survival and transgene expression is more 269 
important than their final identity. Thus, the long-term engraftment and FVV-mediated transgene 270 
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expression in vivo that we demonstrate underpins proposals to use an MSC-based gene therapy approach 271 
for the treatment of lysosomal storage diseases affecting the CNS. 272 
Our work has achieved both high and stable transduction efficiency in both mMSCs and hMSCs, so the 273 
same vector can be employed for pre-clinical and clinical applications. Importantly, FVV transduction is 274 
not enhanced by polybrene46, shown to affect hMSC proliferation capacity47. No additives were used to 275 
achieve high transduction efficiency with FVV. Although high transduction efficiency in hMSCs has 276 
been reported for lentiviral vectors31,48-50, these included viral promoters/enhancers. Even with a viral 277 
promoter driving transgene expression, a SIN lentiviral vector required 3 rounds of transduction to get 278 
92% efficiency in hMSCs50. Given that viral promoters in a retroviral context have been strongly linked to 279 
oncogenesis in other cell types27,30,51, these vector designs are unlikely to be approved for clinical use. The 280 
vector we describe in this paper does not use viral promoters and, thus, has stronger clinical prospects. 281 
In addition to our vector being devoid of viral promoters, FVVs have innate properties that make them 282 
favourable for gene therapy, including a potent transcriptional terminator that prevents transcriptional 283 
read-through52, an integration site bias that does not favour active genes or their regulatory regions53,54 284 
and being derived from a non-human apathogenic virus55. Unfortunately, directly testing our vector’s 285 
safety in MSCs is challenging. No transformation assays exist for hMSCs which senesce in vitro 286 
following long-term culture, while mMSCs undergo a pre-transformation stage when cultured at ambient 287 
oxygen levels in vitro, making them unsuitable for such analysis. However, we monitored GFP 288 
expression during significant in vitro expansion yet saw no indication of clonal dominance, since the MFI 289 
and the percentage of GFP-expressing cells were stable in FVV:PGK-GFP transduced cells (Figs. 3 and 290 
7). Moreover, hMSCs became senescent at the same passage number in transduced and untransduced 291 
cells, indicating that a sub-population was not transformed. Nevertheless, without sensitive 292 
transformation assays available for MSCs, we are unable to draw conclusions on the relative safety of our 293 
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vector in MSCs. Integration site analysis and testing for oncogenic potential in NOD SCID mice may be 294 
appropriate experiments to be carried out prior to clinical translation. 295 
In conclusion, we have developed a potentially safe integrating vector that is highly efficient in both 296 
mouse and human MSCs. For both species of MSC, over 95% express transgene stably for at least 10 297 
passages after transduction. All future combined gene and MSC therapies should take advantage of the 298 
FVV described in this work. 299 
 300 
Materials and Methods 301 
Cell isolation and culture 302 
All cells were cultured under sterile conditions at 5% CO2 and 37℃ in a humidified incubator. The 303 
adherent human embryonic kidney and human fibrosarcoma cell lines; HEK-293T56 and HT108057; were 304 
cultured in DMEM containing 10% FBS. mMSCs were isolated from the bone marrow of 4-6 week old 305 
male C57BL/6 mice. Bone marrow was flushed from the femurs and tibias of 3 mice, pooled and cultured 306 
using the Mesencult Mouse Proliferation kit by StemCell Technologies, UK according to the 307 
manufacturer’s recommended protocol with the exception that dissociation was performed using TrypLE 308 
Express (ThermoFisher Scientific, UK). 309 
Clinical grade human bone marrow MSCs were produced in accordance of the Regulation (EC) No 310 
1394/2007 of the European Parliament and of the Council on advanced therapy medicinal products and 311 
amending Directive 2001/83/EC and Regulation (EC) No 726/2004. For isolation, 2 ml of bone marrow 312 
aspirate was collected from the iliac crests of healthy donors into 100 µl preservative-free heparin. Within 313 
24 hours, cells were seeded at a density of 15-40 000 cells per cm2 in αMEM containing antibiotics and 314 
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10% FBS. After 3 days, non-adherent cells were discarded and adherent cells cultured until confluence. 315 
Cells were maintained using αMEM containing 5% human platelet lysate (Stemulate PL-NH from Cook 316 
Medical, UK). When cells reached over 90% confluence they were dissociated using TrypLE express and 317 
reseeded at a density of 4000 per cm2. All hMSCs were tested for surface marker expression by flow 318 
cytometry and satisfied the recommended minimal criteria58. Over 95% were positive for CD105, CD73 319 
and CD90 expression while less than 2% were positive for the negative markers CD45, CD34, CD3, 320 
CD14, CD19 and HLA-DR. 321 
FVV production 322 
Generation of transfer vector constructs is described in the supplementary material. FVVs were produced 323 
in HEK-293T cells transfected with a 4-plasmid system using PEImax (Polysciences, Germany) at a ratio 324 
of 3:1 PEI:DNA. The 4-plasmid system comprised of one of the pDΦ- transfer plasmids, pcoPG4 325 
(encoding PFV Gag), pcoPPwt (encoding PFV pol), and either pcoPE or pcoSE (encoding PFV or SFVmac 326 
Env, respectively) in the ratio 52:13:6:4, respectively. Plasmids pcoPG4, pcoPPwt and pcoPE have been 327 
described previously59. In a typical transfection, 5 x 106 HEK-293T cells were seeded per 55 cm2 round 328 
culture dish. The next day, cells were transfected with 15 µg of DNA. Following transfection, published 329 
protocols for FVV collection, concentration and storage60 were followed.  330 
FVV transduction and titration 331 
For HT1080 cell transduction, 104 cells were seeded per cm2 surface area. After 16-24 hours, FVV was 332 
added. After a further 16-24 hours, medium was replaced. For vectors expressing GFP, cells were 333 
collected at confluence and the percent of GFP expressing cells (using a vector dilution that gave between 334 
1 and 15% GFP expressing cells) was determined by flow cytometry. The titre was determined by 335 
multiplying the proportion of GFP expressing cells by the number of cells at the time of vector addition. 336 
For ARSA encoding vectors, qPCR analysis determined the FVV DNA content 1 passage post-337 
transduction in transduced HT1080 cells relative to that of cells transduced with GFP vector of known 338 
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titre. For this, the primers 203-F (AGATTGTACGGGAGCTCTTCAC), 203-R 339 
(CAGAAAGCATTGCAATCACC) and dual-labelled probe 203-P (FAM-340 
TACTCGCTGCGTCGAGAGTGTACGA-BHQ-1), which target the FVV LTR, were employed. FVV 341 
DNA content was normalised to the albumin gene using published primers and probe61. 342 
To transduce mMSCs, 2500 cells were seeded per cm2 in the presence of FVV. The cells and vector were 343 
centrifuged at 1200g for 90 minutes at 30℃ then cultured normally. After 16-24 hours, medium was 344 
replaced. For hMSCs, 4000 cells were seeded per cm2. After 16-24 hours, FVV was added and the 345 
cultures centrifuged as for mMSCs. Medium was replaced after 5-8 hours. 346 
Flow cytometry 347 
To assess the percentage of GFP expressing cells and their MFI, at least 10 000 single cells were acquired 348 
using a Beckton Dickinson LSRII. Single cells were selected using forward and side scatter parameters. 349 
Untransduced cells served as a negative control to set the gates in the 488-530/30 channel to determine 350 
the percentage of GFP expressing cells. For mMSCs, which exhibited strong autofluorescence, the GFP 351 
signal in the 488-530/30 channel was plotted against the signal in the 488-610/20 channel. This strategy 352 
distinguished between GFP (stronger in 488-530/30 than 488-610/20) and autofluorescence (similar in 353 
both channels). Example plots are shown in Supplementary Fig. 1. The MFI was calculated by subtracting 354 
the median signal intensity of the GFP negative population from that of the GFP positive population. 355 
Surface marker expression analysis for mMSCs was carried out using the Mouse Mesenchymal Stem Cell 356 
Marker Antibody Panel (R&D systems, UK) according to the manufacturer’s recommended protocol. 357 
Data was acquired using a Beckton Dickinson LSRFortessa. Data analysis was performed using FlowJo. 358 
Functional assays 359 
To quantify intracellular ARSA activity, cells were collected 5 days after reaching confluence and lysed 360 
on ice in 20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 1% Triton X-100 and 2 mM EDTA. Lysates were 361 
17 
 
cleared by centrifugation at 16 000 g and supernatants collected. Protein concentration was determined 362 
using the DC protein assay (Bio-Rad, UK). The ARSA assay performed as previously described42 using 363 
between 1 and 2 µg protein per reaction. To determine ARSA activity in cell-culture medium, mMSCs (2 364 
passages post-transduction) were grown to confluence and complete medium change was performed. 365 
After 5 days, the medium was collected and filtered through a 0.45 µm cellulose acetate syringe filter and 366 
stored at -20℃ until use. For each reaction, 40 µl medium was added. All reactions were performed in 367 
triplicate or quadruplicate in a 96-well microtiter plate. 368 
BODIPY-sulphatide was produced using Lysosulphatide (Matreya, USA), BODIPY FL C16 (Life 369 
Technologies, Canada) and dicyclohexylcarbodiimide (Sigma-Aldrich, Canada) as previously described62. 370 
Patient fibroblasts (MLD or healthy controls) were grown to 75% confluence and BODIPY-sulphatide 371 
was added to a final concentration of 6.7 mM. After 24 hours, cells were rinsed twice with PBS and 372 
diluted MSC cell-culture supernatant added. Cells were collected for high-performance liquid 373 
chromatography analysis after a further 24 hours. BODIPY-lactosylceramide (synthesised as described 374 
for BODIPY-sulphatide) was added as a recovery standard and lipids were extracted using chloroform 375 
and methanol as described63. Chromatographic separations were performed using a Luna C18 column 376 
(Phenomenex; Canada). The mobile phase consisted of solvent A: methanol:water (1:1; v/v) and solvent 377 
B: tetrahydrofuran:methanol (4:1; v/v). The flow rate was 1 ml/min. When eluting the column, the mobile 378 
phase was increased from 40% solvent B to 100% solvent B in 20 minutes, held at 100% solvent B for 10 379 
min, then decreased back to 40% solvent B and held for 10 minutes. The fluorescence detector was set 380 
with an excitation wavelength of 502 nm and emission wavelength of 530 nm. 381 
The differentiation potential of mMSCs into osteocytes, chondrocytes and adipocytes was tested using 382 
StemPro Osteogenesis Differentiation Kit, StemPro Chondrogenesis Kit (both ThermoFisher Scientific) 383 
or MesenCult Adipogenic Stimulatory Supplements, mouse (Stemcell technologies), respectively. For 384 
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hMSCs, osteogenic differentiation was tested as for mMSCs. Manufacturers’ protocols were followed in 385 
all instances. Differentiation was confirmed by staining with Alizarin Red, Alcian Blue or Oil Red O (all 386 
from Sigma-Aldrich, UK), respectively. 387 
Stereotaxic injections and tissue processing 388 
ARSA-/- mice, which contain a large deletion in the ARSA gene (Hess et al., 1996), had previously been 389 
bred onto a C57BL/6 background at the University of Western Ontario, Canada. Procedures were carried 390 
out in compliance with the guidelines set by the Canadian Council for Animal Care. Stereotaxic injections 391 
were carried out as previously described64. Following euthanasia, brains were collected and submerged in 392 
RNAlater (Qiagen, Canada), then frozen at -80℃. Brains were either sectioned using a cryostat for 393 
microscopy or cut into blocks for genomic DNA extraction. Genomic DNA was extracted using the 394 
QIAamp DNA mini kit (Qiagen, UK). The amount of male DNA present in female brains was determined 395 
by qPCR according to published protocols43. The standard curve was generated by adding genomic DNA 396 
from mMSCs to genomic DNA extracted from female ARSA-/- mouse brains. 397 
Microscopy 398 
Photomicrographs of tissue sections were acquired using with the Openlab imaging software (Perkin 399 
Elmer, Canada) connected to an inverted fluorescence Leica DM IRB microscope (Leica Microsystems, 400 
Canada). Fluorescence and light microscopy of cells in vitro was performed using a Nikon Eclipse TE-401 
2000s and images were captured using the Nikon ACT-1 software (Nikon, UK). 402 
Statistical analyses 403 
Graphing and statistical analyses were carried out using GraphPad Prism version 6.07. Asterisks denote 404 
the P value from statistical tests (detailed in Figure legends) where P<0.05=*, P<0.01=**, P<0.001=***. 405 
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Supplementary Materials and Methods 409 
Construction of FVV transfer plasmids 410 
The FVV transfer plasmids were modified from pDΦ34, a gift from D. Russell. The murine PGK promoter 411 
was PCR amplified from pQ-PGK-FLAG-puro (a gift from G. Maertens) using primers PGK-F 412 
(GCATCGATTTCTACCGGGTAGGGGAGGC) and PGK-R 413 
(GCGGTACCAGGTCGAAAGGCCCGGAGATG). The EFS promoter was PCR amplified from the 414 
EF1α promoter in pWPT-GFP (a gift from J. Luban) using primers EFS-F 415 
GCATCGATTGGCTCCGGTGCCCGTCAGT and EFS-R 416 
(GCGGTACCCGCGTCACGACACCTGTGTT). Both promoters were inserted between the ClaI-KpnI 417 
restriction sites of pDΦ. The enhanced GFP open-reading frame was PCR amplified from pWPT-GFP 418 
using primers GFP-F (GCGGTACCATGGTGAGCAAGGGCGAGGA) and GFP-R2 419 
(GCGCGGCCGCAAGCTTCTAGCTACTAGCTAGTCGAG) and cloned into the PCR4-TOPO vector 420 
using the Zero Blunt TOPO PCR Cloning Kit for Sequencing (ThermoFisher scientific). The woodchuck 421 
hepatitis virus post-transcriptional regulatory element (PRE) was PCR amplified from pLVx-EF1α-IRES-422 
mCherry (Clontech, UK) using primers WPRE-F (GCAAGCTTAATCAACCTCTGGATTACAA) and 423 
WPRE-R (GCGCGGCCGCCAGGCGGGGAGGCGGCCCAA) then inserted into PCR4-TOPO 424 
containing GFP between HindIII and NotI restriction sites. GFP-PRE was added between KpnI-NotI 425 
restriction sites to generate plasmids pDΦ-PGK-GFP-wPRE and pDΦ-EFS-GFP-wPRE. A codon 426 
optimised ARSA open-reading frame was amplified from pJO4-ASA (DNA2.0, Menlo Park, CA) using 427 
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primers ARSA-F (GCATCGATGGTACCATGGGTGCGCCCAGATCGTT) and ARSA-R 428 
(GCGGATCCTCACGCATGCGGGTCCGGAC) and inserted between the KpnI and BamHI restriction 429 
sites of pDΦ containing EFS or PGK. The optimised PRE65 was amplified from  pENTR-L5-oPRE-L2 430 
(Addgene plasmid 32414) using primers oPRE-F (GCGGATCCTATACAAAAGTTGTGGAGCA) and 431 
oPRE-R (CAGCGGCCGCACGACAACACCACGGAAT) then inserted between BamHI and NotI 432 
restriction sites to generate pDΦ-PGK-ARSA-oPRE and pDΦ-EFS-ARSA-oPRE. Sequencing confirmed 433 
the correct insert for all plasmids. 434 
 435 
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  609 
Figure Legends 610 
Figure 1 – Schematic of FVVs used in this study. All FVVs contain self-inactivating long-terminal 611 
repeats (SIN-LTR, black boxes) with the U3 region deleted of promoter and enhancer activity. The cis-612 
acting sequences I and II (CASI/II) are viral sequences necessary for virion assembly. Promoter and 613 
transgene of choice are inserted in a multiple cloning site (large white box). A post-regulatory element 614 
(PRE) is included in all constructs to improve transgene expression. Insert abbreviations: PGK – murine 615 
phosphoglycerate kinase promoter; GFP – enhanced green fluorescent protein; EFS – elongation factor 1 616 
alpha short (intron-less version); ARSA – arylsulphatase A (codon optimised for human expression). 617 
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Figure 2 – Effect of FVV envelope on mMSC transduction efficiency and CPE.  (a) The percent of 618 
GFP expressing mMSCs after 1 passage post-transduction with PGK-GFP enveloped with PFV Env 619 
(brick patterned) or SFVmac Env (white) at different MOIs was determined by flow cytometry. The mean 620 
+ SD of biological triplicates is shown. Significant differences between means at each MOI are indicated 621 
by asterisks according to the P value as determined by Two-Way ANOVA with Bonferroni’s multiple 622 
comparisons test. (b-c) Photomicrographs of MSCs 20 hours after vector addition. Scale bar = 50 µm. (b) 623 
Transduced at MOI 30 using PFV Env; (c) Transduced at MOI 30 using SFVmac Env. 624 
Figure 3 – Comparison of the PGK and EFS promoter for sustained GFP expression in mMSCs. (a) 625 
The percentage of mMSCs expressing GFP and (b) their MFI following transduction at MOI 1 (squares) 626 
or MOI 30 (triangles) using FVV:PGK-GFP (white) or FVV:EFS-GFP (black). Flow cytometry analysis 627 
was performed when cells reached ~90% confluence at 1 to 10 passages post-transduction. For each 628 
passage, 1/10th of the total cells were reseeded. Data points show the mean + SD of data from biological 629 
triplicates. Asterisks mark values that are significantly different from the previous passage of the same 630 
sample, as determined by Two-way ANOVA with Bonferroni multiple comparisons tests. (c-d) 631 
Representative photomicrographs of GFP fluorescence in mMSCs transduced at a MOI of 30 with PGK-632 
GFP (c) or EFS-GFP (d), taken 3 passages post-transduction. 633 
Figure 4 – FVV mediates high and sustained expression of ARSA in mMSCs. (a) Lysates of mu-MSC 634 
transduced cells were taken at each passage from 1 to 5 post-transduction. Lysates were mixed with σ-635 
nitrocatechol sulphate in conditions that specifically enable hydrolysis to be catalysed by ARSA. The 636 
nmol of substrate hydrolysed per hour and per mg of total protein per ml are given as mean + SD of data 637 
from biological triplicates. Two-way ANOVA with Bonferroni multiple comparisons tests was used to 638 
identify significant differences between passages of the same transduced mMSCs. Where a passage was 639 
identified to be significantly different from the previous passage of the same population, asterisks are 640 
shown to indicate the P value. (b) The cell-culture medium of mMSCs transduced with the FVV indicated 641 
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was collected and used in the ARSA assay. The nmol of substrate hydrolysed per hour per ml of cell-642 
culture medium is given as mean + SD of data from biological triplicates. (c) Human fibroblasts from 2 643 
normal donors (N1 and N2) and 2 MLD patients’ fibroblasts were loaded with BODIPY-sulphatide then 644 
cultured in the presence of dilute cell-culture medium from FVV:PGK-GFP (white) or FVV:PGK-ARSA 645 
(diamond patterned) transduced mMSCs. After 24 hours, the pmol of BODIPY-sulphatide present in the 646 
samples was determined by HPLC analysis. Values (mean + SD or technical triplicates) are normalised to 647 
BODIPY-lactosylceramide which was added immediately prior to lipid extraction as a recovery standard. 648 
Figure 5 – mu-MSC characteristics are not perturbed by FVV transduction. (a) A panel of 649 
antibodies was used to test surface marker expression on mMSCs transduced or not with FVV. 650 
Representative plots (using mMSCs transduced with FVV:PGK-ARSA) are shown comparing isotype 651 
control antibody staining (blue) to staining with the antibody indicated above each plot (black). (b) The 652 
difference between isotype control and surface marker antibody signal intensity was quantified using the 653 
FlowJo Chi-squared T(x) comparison and plotted for untransduced MSCs (black), or mMSCs transduced 654 
with either FVV:PGK-GFP (white) or FVV:PGK-ARSA (diamond patterned). Higher values of T(x) 655 
show greater difference between surface marker antibody and the isotype control. (c-k) Representative 656 
photomicrographs are shown for mMSCs stained with Alizarin Red (c-e), Alcian Blue (f-h) or Oil Red O 657 
(i-k) without inducing differentiation (c,f,i) or after culturing in osteogenic (d-e), chondrogenic (g-h) or 658 
adipogenic (j-k) differentiation medium. mMSCs were untransduced or transduced with FVV-PGK-659 
ARSA at a MOI of 30 as indicated. 660 
Figure 6 – FVV transduced mMSCs maintain their ability to graft in the brains of mice following 661 
intracerebroventricular delivery. (a) Sectioning of female mouse brains for qPCR analysis to determine 662 
long-term engraftment and distribution of male mMSCs 3 months after the direct delivery of 80 000 663 
mMSCs into the right lateral ventricle (approximate location indicated with solid black circle). The 664 
dashed lines indicate the cuts made to produce 8 sections (numbered). (b) qPCR analysis  to quantify 665 
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mMSCs in the brain sections depicted in a. Each data point represents a section from 1 mouse. White 666 
squares show the engraftment of untransduced mMSCs, whereas black diamonds show the engraftment of 667 
FVV transduced MSCs. Data for each group is from 6 treated mice. Only sections that were above the 668 
detection limit are shown. (c-f) Photomicrographs showing direct GFP fluorescence in mouse brains 669 
following injection of mMSCs transduced by FVV:PGK-GFP. Nuclei, stained with DAPI, are shown in 670 
blue. (c) Right lateral ventricle immediately post-injection; (d) Choroid plexus 45-days post-injection; (e) 671 
parenchyma showing needle track, 45-days post-injection; (f) glomerular layer of olfactory bulb, 45-days 672 
post-injection. 673 
Figure 7 – Human MSCs can be efficiently and stably transduced by FVV. (a) hMSCs from 3 donors 674 
were transduced with FVV:PGK-GFP (white) or FVV:EFS-GFP (black) at the MOIs indicated on the x-675 
axis and the percentage of GFP expressing cells was determined by flow cytometry 1 passage post-676 
transduction. The same vectors, but using the PFV Env, were tested at MOI 50 (brick-patterned bars). (b-677 
c) Photomicrographs of hMSCs 3 days post-transduction (no prior passages post-transduction) with 678 
FVV:PGK-GFP at a MOI of 100 showing normal cell morphology (b) and GFP fluorescence (c). (d-e) 679 
Each time >80% confluence was reached, 1/5th of the hMSCs transduced at MOI 1 (squares) and MOI 680 
100 (circles) were reseeded until 10 passages post-transduction. At each passage, the percentage of GFP 681 
expressing cells (f) and their median fluorescence intensity (g) was determined by flow cytometry. All 682 
panels show the mean + SD of data from biological triplicates. Asterisks in the x-axis labels indicates 683 
passages where cultures growth had slowed down, putatively entering senescence (7-10 post-684 
transduction). 685 
Figure S1 – Flow cytometry to determine percent of GFP expressing mMSCs. FlowJo plots of single 686 
cells in the 488-530/30 versus 488-610/20 channels are shown for untransduced mMSCs, FVV:EFS-GFP 687 
transduced at MOI 1 (showing the weakest GFP signal), and FVV:PGK-GFP transduced at MOI 30 688 
(showing the strongest GFP signal) as indicated. The GFP negative and GFP positive gates were set 689 
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around the untransduced mMSC population and applied to transduced samples to determine the 690 
percentage of GFP expressing mMSCs, as described in Materials and Methods. 691 







